Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer
about
Biomarkers and Targeted Therapy in Pancreatic CancerMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesAdjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporterPatient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic TumorsFrequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
P2860
Q26752755-26C41CB6-4AC9-4157-85DE-B548B6A003ADQ26774636-28B64C2C-E9EA-4869-B771-56C524105F1DQ30277400-E1F62C0C-F731-4E03-8F02-798037422AFAQ36021057-923C06BD-29DF-47E6-8D53-7E1862B513FCQ36177642-C5241564-994E-478B-BDF0-34B8E394BE17Q37280403-B1AF7C1D-C7B1-46C2-B901-EB215EDD8F38Q38717175-F151742C-99A0-47DE-8ECE-D0F14273BDDCQ40332952-FB0B7A8D-3EF0-4E4A-A2EA-8DB177CC4F15Q47141971-6D5C25F0-5352-49C7-A4CF-A13AB5894911Q49586874-09E0AB98-1183-4D58-A8A0-BDF3F1DB990EQ50080994-49E357E6-40CF-48BB-8752-2ADFEC3F83B0Q52739894-B13092F1-E9A7-4173-B62A-0210C31E993EQ55104265-E4CEAFDF-7B4F-44C6-97A4-BF240E7C3305Q57452877-A1C08277-1138-4AE7-A5F8-10D7CA196B88
P2860
Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@ast
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@en
type
label
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@ast
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@en
prefLabel
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@ast
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@en
P2093
P2860
P1433
P1476
Co-treatment with panitumumab ...... aft model of pancreatic cancer
@en
P2093
Alison J Kim
Dustin M Walters
Edward B Stelow
J Thomas Parsons
James M Lindberg
Sara J Adair
Timothy E Newhook
Todd W Bauer
P2860
P304
P356
10.1016/J.NEO.2014.06.004
P577
2014-07-01T00:00:00Z